Dimetacrine

Dimetacrine

SCHEMBL50120

CN(C)CCCN1c2ccccc2C(C)(C)c2ccccc21

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 9/20 1.00
CYP1A2 P05177 8/20 1.00
KMT2A Q03164 4/20 1.00
SLC6A4 P31645 7/20 0.59
HTR1A P08908 7/20 0.59
LMNA P02545 6/20 0.59
MAPT P10636 6/20 0.59
DRD2 P14416 6/20 0.59
HRH1 P35367 6/20 0.59
HTR2A P28223 5/20 0.59
HTR6 P50406 5/20 0.59
CHRM2 P08172 5/20 0.59
CHRM1 P11229 5/20 0.59
DRD1 P21728 5/20 0.59
SLC6A2 P23975 5/20 0.59
ADRA1A P35348 5/20 0.59
OPRM1 P35372 5/20 0.59
DRD3 P35462 5/20 0.59
MTOR P42345 5/20 0.59
KCNH2 Q12809 5/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Dimetacrine SCHEMBL29578094 1.00 CYP2D6 (1.00) CYP2D6CYP1A2KMT2ASLC6A4HTR1A
SCHEMBL11640552 0.88 CYP2D6 (0.78) CYP2D6CYP1A2KMT2ASLC6A4HTR1A
Dimetacrine SCHEMBL3501515 0.87 CYP2D6 (0.75) CYP2D6CYP1A2KMT2ASLC6A4HTR1A
Dimetacrine SCHEMBL3501514 0.87 CYP2D6 (0.75) CYP2D6CYP1A2KMT2ASLC6A4HTR1A
SCHEMBL13231573 0.82 KMT2A (0.68) CYP2D6CYP1A2KMT2ALMNAMAPT
Dimetacrine SCHEMBL28221926 0.82 HRH1 (0.71) CYP2D6CYP1A2KMT2ASLC6A4HTR1A
SCHEMBL17739604 0.81 KMT2A (0.68) CYP2D6CYP1A2KMT2ALMNAMAPT
SCHEMBL12265301 0.79 CYP2D6 (0.66) CYP2D6CYP1A2KMT2ASLC6A4HTR1A
SCHEMBL29025681 0.78 CYP2D6 (0.64) CYP2D6CYP1A2KMT2ASLC6A4HTR1A
SCHEMBL11640659 0.78 KMT2A (0.63) CYP2D6CYP1A2KMT2ASLC6A4HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2653 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4706649-A1 USE OF ADRENALIN FOR THE TREATMENT OF SHOCKS BIOPROJET (FR) 2026-03-11 EP claimed
US-20260001942-A1 TREATMENT OF HEADACHE DISORDERS AND/OR PSYCHIATRIC SYMPTOMS USING ANTI-CGRP ANTIBODIES, AND COMPOSITIONS AND METHODS RELATED THERETO H LUNDBECK AS (DK) 2026-01-01 US claimed
WO-2025262247-A1 TREATMENT OF HEADACHE DISORDERS AND/OR PSYCHIATRIC SYMPTOMS USING ANTI-CGRP ANTIBODIES, AND COMPOSITIONS AND METHODS RELATED THERETO H. LUNDBECK A/S (DK) 2025-12-26 WO claimed
US-12496300-B2 Methods of treating acute depression and anxiety INTRA-CELLULAR THERAPIES, INC. (US) 2025-12-16 US claimed
WO-2025111482-A1 COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS BEXSON BIOMEDICAL, INC. (US) 2025-05-30 WO claimed
EP-4479032-A1 NEUROACTIVE STEROIDS FOR TREATMENT OF CNS-RELATED DISORDERS Sage Therapeutics, Inc. (US) 2024-12-25 EP claimed
US-20240408059-A1 METHOD OF TREATING ADDICTION ANEBULO PHARMACEUTICALS, INC. 2024-12-12 US claimed
EP-3706762-B1 N4-HYDROXYCYTIDINE DERIVATIVE AND ANTI-VIRAL USES RELATED THERETO UNIV EMORY (US) 2024-10-16 EP claimed
US-20240307393-A1 PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT, COMPRISING CDK4/6 INHIBITOR AND TRICYCLIC ANTIDEPRESSANT NATIONAL CANCER CENTER (KR) 2024-09-19 US claimed
US-20240307386-A1 NOVEL METHODS INTRA-CELLULAR THERAPIES, INC. 2024-09-19 US claimed
US-6495154-B1 ADMINISTERING ANTIDEPRESSANTS, ADRENERGIC STIMULANTS, SEROTONIN AGONISTS AND ANTAGONISTS AS THERAPEUTIC AGENTS FOR SEXUAL DISORDERS VIVUS INC. 2002-12-17 US claimed
US-20020161016-A1 As-needed administration of tricyclic and other non-SRI antidepressant drugs to treat premature ejaculation VIVUS LLC (F/K/A VIVUS, INC.) 2002-10-31 US claimed
US-6403597-B1 PRETREATMENT SEXUAL INTERCOURSE VIVUS, INC. 2002-06-11 US claimed
WO-2002041883-A2 AS-NEEDED ADMINISTRATION OF TRICYCLIC AND OTHER NON-SRI ANTIDEPRESSANT DRUGS TO TREAT PREMATURE EJACULATION VIVUS, INC. (US) 2002-05-30 WO claimed
US-20020037828-A1 Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation VIVUS, INC. 2002-03-28 US claimed
US-20010008896-A1 Administration of active agents, including 5-HT receptor agonists and antagonists, to treat premature ejaculation SMITH WILLIAM L (US) 2001-07-19 US claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
US-5922341-A Local administration of pharmacologically active agents to treat premature ejaculation VIVUS, INCORPORATED (US) 1999-07-13 US claimed